Identification of tumor genomic aberrations in BRCA2d prostate tumors may provide insight into the mechanisms of BRCA2-associated prostate carcinogenesis and progression, which could have downstream implications for prevention or therapeutics. The gene discussed is BRCA2; the disease is prostate neoplasm.